膜杰作
Star Staining
抗体来源（Source）
HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1 is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG1 | Mouse kappa
偶联（Conjugate）
HRP-Conjugated
抗体类型（Antibody Type）
Recombinant Monoclonal
种属反应性（Reactivity）
Chemical
免疫原（Immunogen）
SN38-OVA.
特异性（Specificity）
Specifically recognizes the target-SN38.
应用（Application）
| Application | Recommended Usage |
| ELISA | 2-125 ng/mL |
纯度（Purity）
>90% as determined by SDS-PAGE.
纯化（Purification）
Protein A purified/ Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
活性（Bioactivity）-ELISA
Immobilized ADC-SN38 at 1 μg/mL (100 μL/well) can bind HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-PLM685) with a linear range of 2-31.25 ng/mL (QC tested).
Protocol
背景（Background）
SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.
